Business
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer
Study Results to be Presented at the European Society of Medical Oncology's Virtual Plenary and the Society for Gynecologic Oncology 2022 Annual Meeting on
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"Study Results to be Presented at the European Society of Medical Oncology's Virtual Plenary and the Society for Gynecologic Oncology 2022 Annual Meeting on Women's Cancer\nCompany to Host Investor Conference Call on March 17th at 4:30 pm ET\nNEWTON, Mass., March 16, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that results from the Phase 3 SIENDO study will be presented at the European Society of Medical Oncology's (ESMO) Virtual Plenary taking place on Thursday, March 17, 2022. The data will also be presented in a late-breaking abstract at the Society for Gynecologic Oncology (SGO) 2022 Annual Meeting on Women's Cancer taking place March 18-21, 2022, in Phoenix, Arizona.\nDetails for the presentations are as follows:\nESMO Virtual Plenary:\nTitle: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancerPresenter: Professor Ignace Vergote, MD, PhD, Leuven University Hospitals, Leuven, BelgiumDate and Time: Thursday, March 17, 2022, 6:00pm-7:00pm CET/1:00pm-2:00pm ET\nSGO 2022 Annual Meeting on Women's Cancer:\nTitle: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancerPresenter: Professor Ignace Vergote, MD, PhD, Leuven University Hospitals, Leuven, BelgiumSession Type: Oral PresentationSession: Scientific Plenary IV: Late-Breaking AbstractsDate and Time: Saturday, March 19, 2022, 5:19pm-5:27pm MT/7:19pm-7:27pm ET\nConference Call Information Karyopharm will host a conference call Thursday, March 17, 2022, at 4:30 p.m. Eastern Time, to discuss the SIENDO study results. To access the conference call, please dial (888) 349-0102 (local) or (412) 902-4299 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under \"Events & Presentations\" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on ...